[Skip to Content]
[Skip to Content Landing]
December 12, 1986

Bronchodilator Therapy: The Basis of Asthma and Chronic Obstructive Airways Disease Management

Author Affiliations

Boston University School of Medicine

JAMA. 1986;256(22):3163-3164. doi:10.1001/jama.1986.03380220129042

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


This book comprises 11 chapters and three appendixes by 14 contributors, ten from the United Kingdom, three from New Zealand, and one from Israel. Because of differences in regulatory practices, many more agents are available in the United Kingdom than in the United States. Metered-dose inhaler and power-nebulizer administration of bronchodilator aerosols is much more widely used in the UK than in the United States, and, not surprisingly, a clear picture of UK practices in the use of these drugs emerges from the pages of this book. The much wider range between therapeutic efficacy and toxicity of aerosol administration of sympathomimetic amines as compared with their oral use is made very clear.

As might be expected, the material on theophylline therapy is much less authoritative than that on sympathomimetic amines and anticholinergic agents such as ipratropium bromide, since there has been much less experience with theophylline in the UK than